China SXT Pharmaceuticals (SXTC) Cash & Equivalents Growth (3y) (2021 - 2026)
China SXT Pharmaceuticals (SXTC) Cash & Equivalents Growth (3y) (2021 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Equiv. Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - | 21.81% |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn | 11.05% |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn | -4.92% |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn | 7.80% |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn | 19.10% |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn | 12.11% |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn | 27.55% |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | 13.03% |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - | 32.82% |
| 10 | China SXT Pharmaceuticals | 31,562.64 | -28.14 Mn | - | 17.50% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 17.50% |
| Sep 30, 2025 | 10.78% |
| Mar 31, 2025 | 5.20% |
| Sep 30, 2024 | 11.49% |
| Mar 31, 2024 | -3.31% |
| Sep 30, 2023 | 18.82% |
| Mar 31, 2023 | 33.58% |
| Sep 30, 2022 | 18.77% |
| Mar 31, 2022 | 18.77% |
| Sep 30, 2021 | 226.56% |
| Mar 31, 2021 | 172.84% |